Literature DB >> 24716639

Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland's Hepatitis C Action Plan.

S A McDonald1, S J Hutchinson, H A Innes, S Allen, P Bramley, D Bhattacharyya, W Carman, J F Dillon, R Fox, A Fraser, D J Goldberg, N Kennedy, P R Mills, J Morris, A J Stanley, D Wilks, P C Hayes.   

Abstract

Primary goals of the Hepatitis C Action Plan for Scotland Phase II (May 2008-March 2011) were to increase, among persons chronically infected with the hepatitis C (HCV) virus, attendance at specialist outpatient clinics and initiation on antiviral therapy. We evaluated progress towards these goals by comparing the odds, across time, of (a) first clinic attendance within 12 months of HCV diagnosis (n = 9747) and (b) initiation on antiviral treatment within 12 months of first attendance (n = 5736). Record linkage between the national HCV diagnosis (1996-2009) and HCV clinical (1996-2010) databases and logistic regression analyses were conducted for both outcomes. For outcome (a), 32% and 45% in the respective pre-Phase II (before 1 May 2008) and Phase II periods attended a specialist clinic within 12 months of diagnosis; the odds of attendance within 12 months increased over time (OR = 1.05 per year, 95% CI: 1.04-1.07), but was not significantly greater for persons diagnosed with HCV in the Phase II era, compared with the pre-Phase II era (OR = 1.1, 95% CI: 0.9-1.3), after adjustment for temporal trend. For outcome (b), 13% and 28% were initiated on treatment within 12 months of their first clinic attendance in the pre-Phase II and Phase II periods, respectively. Higher odds of treatment initiation were associated with first clinic attendance in the Phase II (OR = 1.9, 95% CI: 1.5-2.4), compared with the pre-Phase II era. Results were consistent with a positive impact of the Hepatitis C Action Plan on the treatment of chronically infected individuals, but further monitoring is required to confirm a sustained effect.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  antiviral therapy; hepatitis C virus; public health intervention

Mesh:

Substances:

Year:  2013        PMID: 24716639     DOI: 10.1111/jvh.12153

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  6 in total

Review 1.  Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis.

Authors:  Philip Vutien; Michelle Jin; Michael H Le; Pauline Nguyen; Sam Trinh; Jee-Fu Huang; Ming-Lung Yu; Wan-Long Chuang; Mindie H Nguyen
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

2.  Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response.

Authors:  Omar Elsherif; Ciaran Bannan; Shay Keating; Susan McKiernan; Colm Bergin; Suzanne Norris
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

3.  Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection.

Authors:  Hamish Innes; Peter Jepsen; Scott McDonald; John Dillon; Victoria Hamill; Alan Yeung; Jennifer Benselin; April Went; Andrew Fraser; Andrew Bathgate; M Azim Ansari; Stephen T Barclay; David Goldberg; Peter C Hayes; Philip Johnson; Eleanor Barnes; William Irving; Sharon Hutchinson; Indra Neil Guha
Journal:  JHEP Rep       Date:  2021-10-07

4.  Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.

Authors:  Alan Yeung; Norah E Palmateer; John F Dillon; Scott A McDonald; Shanley Smith; Stephen Barclay; Peter C Hayes; Rory N Gunson; Kate Templeton; David J Goldberg; Matthew Hickman; Sharon J Hutchinson
Journal:  J Hepatol       Date:  2021-10-09       Impact factor: 25.083

5.  Assessing Hepatitis C Burden and Treatment Effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): Design and Characteristics of Linked and Unlinked Participants.

Authors:  Naveed Zafar Janjua; Margot Kuo; Mei Chong; Amanda Yu; Maria Alvarez; Darrel Cook; Rosemary Armour; Ciaran Aiken; Karen Li; Seyed Ali Mussavi Rizi; Ryan Woods; David Godfrey; Jason Wong; Mark Gilbert; Mark W Tyndall; Mel Krajden
Journal:  PLoS One       Date:  2016-03-08       Impact factor: 3.240

6.  Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.

Authors:  H Midgard; A K Finbråten; K B Malme; R M Berg-Pedersen; L Tanum; I C Olsen; R Bjørnestad; O Dalgard
Journal:  Trials       Date:  2020-06-15       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.